CYTOSPIRE THERAPEUTICS CEO, NATALIE MOUNT, ELECTED A FELLOW OF THE ACADEMY OF MEDICAL SCIENCES
Cytospire Therapeutics is delighted to share that Natalie Mount, our Co-Founder and CEO, has been elected a Fellow of the Academy of Medical Sciences. This prestigious Fellowship recognises Natalie's outstanding leadership in translational science and entrepreneurship, bridging academic discovery, biotechnology and patient impact. With more than 30 years' experience across pharma, biotech and academia, she has played a pivotal role in translating pioneering antibody, cell and gene therapies into viable products, founding three successful UK start‑ups and was recently recognised as Cancer Research Horizons' Woman Entrepreneur of the Year 2025 for her impact on innovation and scientific leadership.
We're delighted to see this recognition of Natalie's career to date and her dedication and success in discovering new therapeutics to address unmet medical needs.
About Cytospire Therapeutics
Cytospire is developing an innovative portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells. Our core technology allows binding and activation of both tissue/tumour and blood resident gamma delta T cells. This opens a path to safer and more efficacious targeting of well-validated antigens that are intractable to CD3 T cell engagers due to toxicity. There are broad opportunities for Cytospire's gamma delta T cell engagers in solid and haematological malignancies, as well as in autoimmune disease.
Based in London, UK, Cytospire Therapeutics is backed by a strong syndicate of life science investors including Abingworth, 4BIO Capital, Servier Ventures, British Business Bank, Sound Bioventures, LifeArc Ventures and Criteria Bio Ventures.
For more information, visit www.cytospire.com
